Lantern Pharma’s treatment of Mantle Cell Lymphoma was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LTRN:
Lantern Pharma’s treatment of Mantle Cell Lymphoma was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LTRN: